A drug nobody can legally buy yet already has a black market. Somebody's selling retatrutide, and it isn't Lilly. This is GLP-1 Daily. Today, who's chasing an unapproved drug and why Wegovy pill generics are so far off. Plus, which beyond-weight-loss promises actually held up. Let's start with those vials, and who's doing the accusing. Kelly Bilodeau, writing in PharmaVoice:
Eli Lilly is no stranger to competition from compounded versions of its tirzepatide GLP-1 diabetes and weight loss drugs. But the problem recently took a turn into uncharted territory when medical spas, online sellers and other businesses began marketing products purporting to contain its investigational obesity drug retatrutide.
Retatrutide is still in phase 3. There's no legal route for any patient to get it, and med spas and online sellers are marketing it anyway. According to Lilly's own release, they're pitching it as a 'weight loss hack.' Lilly says it's filed six lawsuits and is going to courts, law enforcement and regulators. Those are still allegations at this point, not findings. And Jayne Hornung at MMIT thinks the active ingredient is coming from overseas research suppliers. So that 'substantial weight loss' in the pitch? That came from Lilly's trials. Nobody knows what's actually in that vial. Compounders at least work in a legal lane. They make versions of an approved drug when federal requirements are met. Here there's no approved product to copy. And people are still lining up. Same patient who got priced out of Zepbound or lost a compounded supply, different storefront. Yeah, the demand is a real signal, and I'd put that in the headline right next to the lawsuits. But a gray-market powder with no label and no monitoring? All it does is move the risk onto the patient. INTO BIOTECH writes:
Novo Nordisk’s (NVO) oral obesity drug, the Wegovy pill (oral semaglutide 25 mg), passed DKK 3.2 billion in quarterly sales just two quarters after its U.S. launch. Yet even once its patents start to expire, this pill will be far harder to copy than the injection.
Prescriptions more than doubled, about 1.3 million to 2.9 million, and revenue per script fell roughly thirty-eight percent. INTO BIOTECH reads that as cash-pay at a hundred forty-nine to two ninety-nine a month. So the fastest-growing payer for this pill may be the patient's own debit card. Sourcing line, though. The DKK 3.2 billion is Novo's number, straight from its own Q1 and Q2 reports. The cash-pay explanation is the author's inference. Plausible. I'd probably bet on it. Still an inference. Same demand we just heard chasing retatrutide through med spas. The difference is there's a legal door here. You just need three hundred bucks a month to walk through it. And nobody should circle 2039 on a calendar. That's the author's reading of Orange Book patents, checked October 8. The last two basically cover today's tablet, and swapping out the absorption enhancer drops absorption to about sixty percent, per Novo's own data. Apotex filed anyway in April. The litigation will tell us more than any patent chart, and for now, nothing changes at the pharmacy counter. From Inside Peptides:
GLP-1 medicines now have FDA-approved uses well beyond weight loss and blood sugar: lowering heart-attack and stroke risk, slowing kidney disease in type 2 diabetes, treating a serious form of fatty liver disease, and treating obstructive sleep apnea. But not every hopeful headline has held up. Two large Alzheimer's trials failed, a phase 3 Parkinson's trial was negative, and the evidence for alcohol use disorder is still early.
I read this Inside Peptides scorecard like a claims form. Heart, kidney, liver, sleep apnea. Every approved row is a diagnosis code, and a diagnosis code is a door. Kidney disease in type 2 diabetes? Better have the type 2 diabetes. And those doors opened fast. Approvals in March 2024, January 2025, August 2026. But the line I'd underline is their own: each approval covers a specific product, for a specific population and use. So read the row. Skip the vibe. Then there's the column nobody puts on a billboard. Two large Alzheimer's trials, failed. A phase 3 in Parkinson's, negative. Alcohol use disorder? Still early. Honestly, that red ink is what keeps the green ink honest. Heart failure, knee osteoarthritis, peripheral artery disease all have positive trials and no US indication, so there's no door yet. And when one does open, it'll fit the people who were enrolled to prove it. What the evidence covers depends on who got studied. If you're finding GLP-1 Daily useful, please subscribe or leave a review wherever you're listening. Reviews help other people discover the show, and we're grateful you're here.
Links to every story we covered are in the show notes, if you want to dig deeper into the ones that caught your attention. Thanks for listening to GLP-1 Daily. We'll be back tomorrow with another briefing. This is a Lantern Podcast.